1. Protein Tyrosine Kinase/RTK
  2. Syk


Syk (Spleen tyrosine kinase) is a cytosolic non-receptor protein tyrosine kinase (PTK) that is expressed at high levels, both in hematopoietic cells (such as mast cells, B lymphocytes, T lymphocytes, neutrophils, dendritic cells, and macrophages) and in non-hematopoietic cells.

Syk mediates key signal transduction pathways following the activation of immune cell receptors. Syk associates with different receptors on the surface of various cells such as B cells, mast cells, monocytes, macrophages, and neutrophils, and even osteoclasts and breast cancer cells. Following the engagement of these receptors with their ligands, SYK is activated and orchestrates diverse cellular responses, including cytokine production (in T cells and monocytes) and phagocytosis (in macrophages).

Syk Related Products (57):

Cat. No. Product Name Effect Purity
  • HY-13518
    Piceatannol Inhibitor 98.90%
    Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI)[1]. Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties[2]. Piceatannol induces apoptosis in DLBCL cell lines[3]. Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells[4].
  • HY-13038A
    Fostamatinib Inhibitor 99.50%
    Fostamatinib (R788) is the oral proagent of the active compound R406[1]. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM[2]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[3].
  • HY-15968
    Entospletinib Inhibitor 99.88%
    Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
  • HY-12067
    R406 Inhibitor 98.72%
    R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a Ki of 30 nM, potently inhibits Syk kinase activity in vitro with an IC50 of 41 nM, measured at an ATP concentration corresponding to its Km value. R406 reduces immune complex-mediated inflammation[1]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[2].
  • HY-15323
    PRT062607 Hydrochloride Inhibitor 98.68%
    PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models[1][2].
  • HY-160930
    TOP1288 Inhibitor
    TOP1288 is a narrow spectrum kinase inhibitor for P38α, Src and Syk kinase, with IC50 of 116nM, 24nM and 659nM, respectively. TOP1288 inhibits inflammatory cytokine release from inflamed biopsies and myofibroblasts[1].
  • HY-112390C
    Syk Inhibitor II hydrochloride Inhibitor
    Syk Inhibitor II hydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II hydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II hydrochloride shows less potent against other kinases and has anti-allergic effect[1].
  • HY-13038AR
    Fostamatinib (Standard) Inhibitor
    Fostamatinib (Standard) is the analytical standard of Fostamatinib. This product is intended for research and analytical applications. Fostamatinib (R788) is the oral proagent of the active compound R406[1]. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM[2]. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM)[3].
  • HY-131341
    Syk-IN-4 Inhibitor
    Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers[1].
  • HY-15322
    PRT062607 Inhibitor
    PRT062607(P505-15; PRT-2607; BIIB-057) is a highly specific and potent inhibitor of Syk with IC50 of 1-2 nM; >80-fold selective for Syk than Fgr, Lyn, FAK, Pyk2 and Zap70.
  • HY-151634
    Syk-IN-6 Inhibitor
    Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML)[1].
  • HY-P2504
    Syk Kinase Peptide Substrate, Biotin labeled
    Syk Kinase Peptide Substrate, Biotin labeled is a biotin-labled Syk kinase peptide substrate.
  • HY-12657
    Syk-IN-1 Inhibitor 99.18%
    Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM[1].
  • HY-145598
    Sovleplenib Inhibitor 99.56%
    Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP)[1].
  • HY-109091B
    Lanraplenib succinate Inhibitor 98.58%
    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3].
  • HY-76474
    BAY 61-3606 Inhibitor 98.21%
    BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM[1]. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell[2]. BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates[3]. Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells[4].
  • HY-112319
    MK-8457 Inhibitor
    MK-8457 is a dual SYK/ZAP70 inhibitor. MK-8457 can be used for research of rheumatoid arthritis[1].
  • HY-15999A
    Cerdulatinib hydrochloride Inhibitor 99.89%
    Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies[1][2].
  • HY-12974
    PRT-060318 Inhibitor 99.36%
    PRT-060318 (PRT318) is a novel selective inhibitor of the tyrosine kinase Syk with an IC50 of 4 nM.
  • HY-N3702
    Dehydroabietinol Inhibitor
    Dehydroabietinol is an abietane diterpenoid. Dehydroabietinol has kinase inhibition activity for spleen tyrosine kinase (SYK) with an IC50 value of 46.4 μM. Dehydroabietinol can be used for the research of immune-mediated disease[1].